Regeneron公布超罕见遗传性疾病进行性肌肉骨化症成人患者三期临床试验积极结果,显示Garetosmab可预防超过99%的异常骨化。
Regeneron公布超罕见遗传性疾病进行性肌肉骨化症成人患者三期临床试验积极结果,显示Garetosmab可预防超过99%的异常骨化。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.